• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vectura

Appeals court nixes GSK’s petition for new trial in Vectura patent spat

November 20, 2020 By Nancy Crotti

The Federal Circuit Court has rejected Glaxo Smith Kline’s (NYSE:GSK) petition for a new trial in a patent case brought by British inhaler company Vectura. The circuit court upheld a May 2019 jury verdict in U.S. District Court for the District of Delaware, awarding Ventura $89.7 million damages for the period from August 2016 through […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Respiratory Tagged With: GlaxoSmithKline plc, Vectura

Judge adds $10m in damages in Vectura-GSK patent spat

September 16, 2019 By Nancy Crotti

vectura-logo

This article has been updated with a statement from Glaxo Smith Kline. A federal judge in Delaware has awarded British inhaler company Vectura an additional $10.5 million in compensatory damages from Glaxo Smith Kline (NYSE:GSK) in a patent dispute. In May, a jury awarded Vectura $89.7 million in damages for the period from August 2016 […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Respiratory, Uncategorized Tagged With: GlaxoSmithKline plc, Vectura

Vectura seeks another $44M in GSK patent win

June 28, 2019 By Nancy Crotti

vectura-logo

Fresh off its $89.7 million jury award in a patent infringement case against GlaxoSmithKline (NYSE:GSK), British inhaler company Vectura has petitioned the court for an additional $44 million. On May 16, a jury in U.S. District Court for the District of Delaware awarded Vectura damages for the period from August 2016 through December 2018 for […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Respiratory, Uncategorized Tagged With: GlaxoSmithKline plc, Vectura

Vectura wins $89.7m in patent infringement case against GlaxoSmithKline

May 6, 2019 By Danielle Kirsh

vectura-logo

Vectura said this week that it has settled a U.S. patent infringement litigation with GlaxoSmithKline and was awarded $89.7 million in damages. Following a jury trial in the U.S. District Court for the District of Delaware, Ventura was awarded damages for the period from August 2016 through December 2018 for an infringement on Vectura’s U.S. […]

Filed Under: Legal News Tagged With: GlaxoSmithKline plc, Vectura

Novartis launches COPD inhalers in China

March 22, 2019 By Sarah Faulkner

Novartis

Novartis (NYSE:NVS) has launched its Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease. The Ultibro Breezhaler system is a once-daily fixed-dose combination of indacaterol and glycopyrronium bromide. Seebri Breezhaler is a fixed-dose formulation of glycopyrronium bromide. The inhaled therapies are approved in more than 90 countries, including the U.S. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Novartis, soseigroup, Vectura

Pulmatrix licenses inhaled COPD drug to Vectura

September 6, 2017 By Sarah Faulkner

Pulmatrix

Pulmatrix (NSDQ:PULM) said today that it licensed its inhaled COPD drug to Vectura. The PUR0200 compound combines tiotropium bromide and Pulmatrix’s iSperse drug-delivery technology. Vectura plans to use its dry powder inhaler device to deliver PUR0200, the company said. “Vectura has deep experience with inhaled drugs and innovative dry powder delivery technologies which makes them an […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc., Vectura

Vectura wins IND for drug-device combo for pediatric asthma

January 25, 2017 By Sarah Faulkner

Vectura wins IND for drug-device combo for pediatric asthma

Vectura said yesterday that the FDA approved an Investigational New Device application for its drug-device combination to treat asthma in children 12 months to 8 years old. The UK-based company’s device, VR647, uses the Akita Jet nebulizer for the delivery of nebulized budesonide. Vectura’s drug-device combination product provides faster delivery time and better lung deposition of budesonide, […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Respiratory Tagged With: Vectura

Vectura on the hunt for specialized lung drug business

November 1, 2016 By Sarah Faulkner

Vectura wins IND for drug-device combo for pediatric asthma

(Reuters) — James Ward-Lilley, the former AstraZeneca executive who created a UK respiratory medicine business in June by merging Vectura and SkyePharma, is already thinking about his next deal. This time he’d like to buy a company with an established U.S. sales force to accelerate the group’s ambitions as it develops specialized lung drugs that are […]

Filed Under: Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Vectura

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS